DAWN

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company went public in May 2021 and focuses on developing and commercializing targeted therapies for patients with genetically defined cancers. Day One achieved a significant milestone in 2024 with the FDA approval and commercial launch of its lead product OJEMDA (tovorafenib), marking its transition from a purely clinical-stage company to a commercial-stage biopharmaceutical enterprise with growing product revenues.